About Us

VPC NeuroTherapeutics Inc. is a start-up pharmaceutical company at the preclinical/clinical stage, established by Dr. Kwiecien in 2021 in Hamilton, Ontario, Canada to develop, obtain regulatory approvals and market effective treatments for severe, destructive inflammatory disease initiated by neurotrauma and stroke.

Dr. Kwiecien's systematic studies led to elucidation of the pathogenesis of this disease and to identification of the therapeutic target: severe inflammation which not only causes additional destruction in the injured spinal cord but also damages blood vessels in not-yet-destroyed tissue, causing excessive leaking, swelling, and paralysis.

The oral administration of xanthohumol, a small flavonoid molecule isolated from hops, inhibits the severity of neuroinflammation, shortens its course, and preserves spinal cord from destruction. The anti-neuroinflammatory effect of xanthohumol is proprietary.

In a recent clinical study by Dr. Dabrowski in Lublin, Poland, its anti-inflammatory activity consistently resulted in recovery of motor function in spinal cord injury patients, attributed to inhibition of vascular damage and elimination of swelling. Unprecedented.

The company is engaged in regulatory approvals for an oral formulation with synthesized xanthohumol in preclinical studies and clinical trials towards completion of Clinical Trial Phase 2, anticipated in 4 years.

Key Facts